DUET Trial: Low-Sodium Oxybate Significantly Consolidates Nighttime Sleep Architecture in Narcolepsy

Why It Matters

LXB’s ability to restore restorative sleep and reduce daytime sleepiness offers clinicians a dual‑action therapy, addressing a core unmet need in narcolepsy management and potentially reducing long‑term cardiovascular risk from high sodium exposure.

Key Takeaways

• LXB added 45 minutes of deep (N3) sleep in DUET trial
• ESS scores dropped 7.7 points, normalizing daytime sleepiness
• 93% of participants reported overall condition improvement
• 61.8% experienced mild‑to‑moderate adverse events; no serious events
• LXB provides 92% less sodium than traditional sodium oxybate

Pulse Analysis

Narcolepsy’s hallmark triad of excessive daytime sleepiness, cataplexy, and fragmented nighttime sleep has long challenged clinicians seeking comprehensive treatment. While earlier phase‑3 trials of low‑sodium oxybate focused on daytime outcomes, the DUET study uniquely paired polysomnographic data with patient‑reported measures to evaluate the drug’s impact on sleep architecture. Conducted across multiple centers, the open‑label, real‑world design enrolled 55 participants, with 34 completing the full assessment after individualized titration and a two‑week stable dosing period. This methodology mirrors everyday clinical practice, offering insight into how LXB performs outside tightly controlled trial environments.

The results are striking: participants experienced an average 45‑minute boost in deep N3 sleep, a 13‑point reduction in sleep‑stage transitions, and three fewer nocturnal awakenings, indicating a more consolidated and restorative night. These objective gains translated into substantial daytime benefits—ESS scores fell by 7.7 points, moving patients from severe sleepiness to near‑normal levels, and over 90% reported a meaningful overall improvement. Patient‑centered outcomes such as the PGI‑C and sleep‑quality ratings also rose sharply, underscoring the therapeutic relevance of nighttime sleep restoration for daytime functioning.

From a business perspective, LXB’s low‑sodium formulation differentiates it in a market dominated by sodium‑rich oxybate products, mitigating long‑term cardiovascular concerns associated with high sodium intake. The safety profile remained favorable, with only mild‑to‑moderate adverse events and no serious incidents, reinforcing confidence for prescribers. As payers increasingly value outcomes that reduce comorbidities, LXB’s dual benefit—enhanced sleep architecture and daytime alertness—positions it as a compelling option for both NT1 and NT2 patients, potentially expanding its market share and driving further adoption in sleep‑disorder clinics.